Effects of renalase deficiency on liver fibrosis markers in a nonalcoholic steatohepatitis mouse model.
Progression of nonalcoholic steatohepatitis (NASH) is attributed to several factors, including inflammation and oxidative stress. In recent years, renalase has been reported to suppress oxidative stress, apoptosis and inflammation. A number of studies have suggested that renalase may be associated with protecting the liver from injury. The present study aimed to clarify the effects of renalase knockout (KO) in mice with NASH that were induced with a choline‑deficient high‑fat diet (CDAHFD) supplemented with 0.1% methionine. Wild type (WT) and KO mice (6‑week‑old) were fed a normal diet (ND) or CDAHFD for 6 weeks, followed by analysis of the blood liver function markers and liver tissues. CDAHFD intake was revealed to increase blood hepatic function markers, lipid accumulation and oxidative stress compared with ND, but no significant differences were observed between the WT and KO mice. However, in the KO‑CDAHFD group, the Adgre1 and Tgfb1 mRNA levels were significantly higher, and α‑SMA expression was significantly lower compared with the WT‑CDAHFD group. Furthermore, the Gclc mRNA and phosphorylated protein kinase B (Akt) levels were significantly lower in the KO‑ND group compared with the WT‑ND group. The results of the current study indicated that as NASH progressed in the absence of renalase, oxidative stress, macrophage infiltration and TGF‑β expression were enhanced, while α‑SMA expression in NASH may be partly suppressed due to the decreased phosphorylation of Akt level.
['Tokinoya|Katsuyuki|K|', 'Sekine|Nanami|N|', 'Aoki|Kai|K|', 'Ono|Seiko|S|', 'Kuji|Tomoaki|T|', 'Sugasawa|Takehito|T|', 'Yoshida|Yasuko|Y|', 'Takekoshi|Kazuhiro|K|']
D000818:Animals D015415:Biomarkers D005786:Gene Expression Regulation D008106:Liver Cirrhosis, Experimental D051379:Mice D018345:Mice, Knockout D008995:Monoamine Oxidase D065626:Non-alcoholic Fatty Liver Disease D015398:Signal Transduction
renalase liver oxidative stress Akt transforming growth factor‑β α‑smooth muscle actin